Durable Responses Achieved with AM0010.

Cancer discovery ·第 6 卷 ·第 12 期 ·0000-00-00

摘要

In a phase Ib trial, a combination of the experimental immunotherapy AM0010, a PEGylated form of the recombinant human cytokine IL10, and the anti-PD-1 checkpoint inhibitor pembrolizumab was well tolerated and effective at controlling tumors in some patients with advanced renal cell carcinoma, non-small cell lung cancer, and melanoma.

文献信息

期刊

Cancer discovery

期刊简称

Cancer Discov

ISSN

2159-8274

DOI

10.1158/2159-8290.CD-NB2016-125

发表日期

0000-00-00

收录日期

2016-11-02

更新日期

2016-12-06

语言

英语

国家/地区

United States

NLM ID

101561693

外部链接

PubMed 原文 DOI: 10.1158/2159-8290.CD-NB2016-125 查看期刊详情

分析服务

Durable Responses Achieved with AM0010.

联系地址

微信公众号